A F Baker|R T Dorr - JoVE Visualize

Showing results (91-100 of 154) with videos related to

Pageof 16

Sort By:

Anti-Cancer Drug Design|November 10, 1998

Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediolsR T Dorr, W Bellamy, J D Liddil, et al.

Toxicology|January 29, 1993

Administration of melanotropic peptides during gestation in the rodentB V Dawson, C A Ford, H Holloway, et al.

Cancer Treatment Reports|March 1, 1987

Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotesR T Dorr, D S Alberts, J Einspahr, et al.

Plant Physiology|December 1, 1984

beta-Glucosidase Activity in Corn Roots: Problems in Subcellular FractionationG Nagahashi, A F Baker

Cancer Research|February 1, 1993

Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cellsN G Shipp, R T Dorr, D S Alberts, et al.

Cancer Chemotherapy and Pharmacology|February 28, 2001

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumorsC W Taylor, R T Dorr, P Fanta, et al.

Breast Cancer Research and Treatment|January 1, 1997

Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancerC W Taylor, W S Dalton, K Mosley, et al.

Biopharmaceutics & Drug Disposition|July 1, 1994

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in ratsS O Ugwu, J Blanchard, L D Nguyen, et al.

Cancer Treatment Reports|February 1, 1979

Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugsR T Dorr, C E Trinca, K Griffith, et al.

Pharmaceutical Research|July 11, 2000

Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-IR Bhardwaj, M E Hadley, R T Dorr, et al.

Pageof 16

Showing results (91-100 of 154) with videos related to

Sort By:

Pageof 16

Anti-Cancer Drug Design|November 10, 1998

Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediolsR T Dorr, W Bellamy, J D Liddil, et al.

Toxicology|January 29, 1993

Administration of melanotropic peptides during gestation in the rodentB V Dawson, C A Ford, H Holloway, et al.

Cancer Treatment Reports|March 1, 1987

Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotesR T Dorr, D S Alberts, J Einspahr, et al.

Plant Physiology|December 1, 1984

beta-Glucosidase Activity in Corn Roots: Problems in Subcellular FractionationG Nagahashi, A F Baker

Cancer Research|February 1, 1993

Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cellsN G Shipp, R T Dorr, D S Alberts, et al.

Cancer Chemotherapy and Pharmacology|February 28, 2001

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumorsC W Taylor, R T Dorr, P Fanta, et al.

Breast Cancer Research and Treatment|January 1, 1997

Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancerC W Taylor, W S Dalton, K Mosley, et al.

Biopharmaceutics & Drug Disposition|July 1, 1994

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in ratsS O Ugwu, J Blanchard, L D Nguyen, et al.

Cancer Treatment Reports|February 1, 1979

Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugsR T Dorr, C E Trinca, K Griffith, et al.

Pharmaceutical Research|July 11, 2000

Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-IR Bhardwaj, M E Hadley, R T Dorr, et al.

Pageof 16